Actively Recruiting
Evaluating the Safety and Effectiveness of TQB6411 Injections in Adults with Advanced Lung Cancer
Led by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Updated on 2026-09-08
465
Participants Needed
38
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of TQB6411 for injection in adults with advanced lung cancer. This phase IbII clinical trial aims to find the recommended phase II dosage and assess how well the treatment works in shrinking tumors or controlling the disease. The study is sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and focuses on patients aged 18 to 75 years with confirmed lung cancer. Participants will receive TQB6411 injections either every 21 days or every 28 days as treatment cycles. The study involves only one treatment group where all participants receive TQB6411. Each cycle of treatment is followed by assessments to monitor response and safety. The trial includes dose evaluation and efficacy measurement over several months, with extended follow-up for survival and side effects lasting up to three years. During the study, participants will undergo medical evaluations including laboratory tests, imaging scans to measure tumors, and monitoring of adverse events. Blood samples will be taken to study drug levels and antibodies. The main outcomes measured include tumor response rates, disease control, duration of response, progression-free and overall survival. Safety is closely monitored throughout the study. The total participation time may last up to three years, including treatment and follow-up visits.
CONDITIONS
Brief Title
A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
Research Team
S
Shengxiang Ren, Doctor
Z
Zhijie Wang, Doctor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here